Conversely, a recent meeting report has cast doubt on ROR1-targeted CAR-T therapy due to its lack of efficacy in reducing tumor burden and high pulmonary toxicity [21]; the field may become further clouded by a recent withdrawal of a clinical trial with unknown reason (clinicaltrials.gov identifier: NCT02194374). Here, ROR1 is linked to neoplasm.